Aldeyra Therapeutics, Inc. (ALDX) stock
ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.69+0.02 (+3.63%)
Close on Nov 17, 2026Market cap $41.86MP/E –Yield –
Earnings
Aldeyra Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q1 FY2023
–
EPS, Q1 FY2023
-$0.27
-$0.29 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Aldeyra Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | – | – | -$0.27 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | -$0.25 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 5, 2022before the open | – | – | -$0.30 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | – | – | -$0.29 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 17, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021before the open | – | – | -$0.27 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 7, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 12, 2020before the open | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 7, 2019before the open | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 8, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 9, 2019before the open | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 8, 2019before the open | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 14, 2018before the open | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 9, 2018before the open | – | – | – | Filing |
| Q4 FY2017ended Dec 31, 2017 | Mar 29, 2018before the open | – | – | – | Filing |
| Q3 FY2017ended Sep 30, 2017 | Nov 9, 2017before the open | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Aug 8, 2017before the open | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | May 15, 2017before the open | – | – | – | Filing |
| Q4 FY2016ended Dec 31, 2016 | Mar 30, 2017before the open | – | – | – | Filing |
| Q3 FY2016ended Sep 30, 2016 | Nov 14, 2016before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Aldeyra Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Aldeyra Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Aldeyra Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- News
- News
- Update
- News
- Update
- Update
- Update
See a number that looks wrong?